Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study
Public ClinicalTrials.gov record NCT05131477. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate-to-Severe Atopic Dermatitis
Study identification
- NCT ID
- NCT05131477
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Kymab Limited
- Industry
- Enrollment
- 390 participants
Conditions and interventions
Conditions
Interventions
- Amlitelimab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 12, 2021
- Primary completion
- Apr 25, 2023
- Completion
- Feb 20, 2024
- Last update posted
- Jul 2, 2025
2021 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site Number: 1018 | Fremont | California | 94538-1601 | — |
| Investigative site #1022 | Sacramento | California | 95816-3370 | — |
| Investigative Site Number: 1006 | Boca Raton | Florida | 33428 | — |
| Investigative Site Number: 1001 | Clearwater | Florida | 33756-3424 | — |
| Investigative Site Number: 1019 | Coral Gables | Florida | 33134-2950 | — |
| Investigative Site Number: 1007 | Miami | Florida | 33176-2264 | — |
| Investigative Site Number: 1013 | Tampa | Florida | 33615-3816 | — |
| Investigative Site Number: 1004 | Savannah | Georgia | 31406-2668 | — |
| Investigative Site Number: 1010 | Clarksville | Indiana | 47129-2201 | — |
| Investigative Site Number: 1015 | Indianapolis | Indiana | 46250-2041 | — |
| Investigative Site Number: 1021 | Louisville | Kentucky | 40241 | — |
| Investigative Site Number: 1011 | Towson | Maryland | 21204-7448 | — |
| Investigative Site Number: 1014 | Beverly | Massachusetts | 01915-1666 | — |
| Investigative Site Number: 1012 | Troy | Michigan | 48084-3536 | — |
| Investigative Site Number: 1005 | Tulsa | Oklahoma | 74136-7049 | — |
| Investigative Site Number: 1017 | Portland | Oregon | 97223-6683 | — |
| Investigative Site Number: 1009 | Portland | Oregon | 97239 | — |
| Investigative Site Number: 1003 | Anderson | South Carolina | 29621-2062 | — |
| Investigative Site Number: 1008 | Murfreesboro | Tennessee | 37130-2450 | — |
| Investigative site #1023 | Mansfield | Texas | 76063 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05131477, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05131477 live on ClinicalTrials.gov.